In biotech, even the most promising therapies can stumble if the process behind them isn’t solid. Scale-up challenges, poor technology choices, or inefficient purification steps can turn an exciting pre-clinical program into a stalled project.
Did you know that early-stage companies can leverage Millipore Sigma’s Process Development Scientists—at no cost? This program provides biotech companies with access to hundreds of scientists and engineers who specialize in solving exactly these kinds of problems. Through an strictly confidential process that requires no IP sharing, PD trials can take place at the customer side or in one of the M Lab™ Collaboration Centers. By drawing on decades of leadership in cell culture, chromatography, filtration, and more, this resource helps emerging biotechs conserve their resources and accelerate progress toward their next inflection point.
How It Works
The scope of support spans both upstream and downstream process development.
- Upstream production: optimization of media and feed strategies, cell line development support, cost-of-goods planning, harvest recovery optimization, and the use of advanced analytical tools such as real-time Raman monitoring.
- Downstream recovery: comprehensive review of sterile filtration requirements chromatography optimization for improved purity and yield, ultrafiltration/diafiltration strategies, virus filtration validation, and overall troubleshooting of any unit operation.
These aren’t just high-level consultations. Companies can run customized bench-scale trials—either on-site or virtually with the MilliporeSigma PDS team. Each collaboration results in a detailed technical report with data that companies can use to make confident next steps.
Confidential Collaboration
The ability to share openly is crucial. MilliporeSigma underscores that all engagements with its PDS team are conducted under strict confidentiality. Startups retain control over their intellectual property while still benefiting from expert feedback and real-world data. This reassurance lowers the barrier to collaboration. For companies guarding breakthrough therapies, knowing they can engage with outside experts without risk is essential.
Who Benefits Most
The program is designed for versatility, covering a broad range of modalities from monoclonal antibodies and recombinant proteins, to RNA, cell, and gene therapies.
For emerging biotech companies, the appeal is clear: starting smart and scaling smoothly can save months of trial and error. For larger companies exploring new therapeutic areas, the collaboration provides a way to de-risk strategies before making bigger investments.
Why It Matters
The biotech industry often talks about speed, but speed without reliability can be a trap. A process that works in the lab may fall apart at scale if key steps aren’t designed with production in mind. That’s where expert input makes the difference.
By giving companies access to experienced scientists, MilliporeSigma is helping them avoid predictable pitfalls. The ability to leverage expertise at the right moment—without cost—can mean reaching milestones faster, securing funding more easily, and ultimately bringing therapies to patients sooner.
A Strategic Play, Too
By embedding itself in the workflows of young companies, MilliporeSigma positions itself as a trusted partner for the long haul. Biotechs that benefit from this free support are more likely to adopt the company’s platforms and technologies as they grow.
But for startups, that doesn’t diminish the immediate value. The chance to tap into high-level process expertise without stretching budgets is rare and potentially transformative. In a field where every decision shapes the timeline to patients, this is more than just a useful service—it’s a competitive edge.
